IPO Timeline Raw facts
Company Overview
| Stock Name | Hightide-B |
|---|---|
| Stock Code | 02511 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司為一間生物制藥公司,專注于就代謝及消化系統疾病的治療發現、開發及商業化多功能及多靶點療法。 |
| Listing Date | 2023-12-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省深圳市龍崗區吉華街道甘李二路中海信創新產業城18B-102 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.hightidetx.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 11.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 39.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 83,472,750 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 0 |
| 2 lots | 1,000 | HK$ 0 |
| 3 lots | 1,500 | HK$ 0 |
| 4 lots | 2,000 | HK$ 0 |
| 5 lots | 2,500 | HK$ 0 |
| 6 lots | 3,000 | HK$ 0 |
| 7 lots | 3,500 | HK$ 0 |
| 8 lots | 4,000 | HK$ 0 |
| 9 lots | 4,500 | HK$ 0 |
| 10 lots | 5,000 | HK$ 0 |
| 12 lots | 6,000 | HK$ 0 |
| 14 lots | 7,000 | HK$ 0 |
| 16 lots | 8,000 | HK$ 0 |
| 18 lots | 9,000 | HK$ 0 |
| 20 lots | 10,000 | HK$ 0 |
| 30 lots | 15,000 | HK$ 0 |
| 40 lots | 20,000 | HK$ 0 |
| 50 lots | 25,000 | HK$ 0 |
| 60 lots | 30,000 | HK$ 0 |
| 70 lots | 35,000 | HK$ 0 |
| 80 lots | 40,000 | HK$ 0 |
| 90 lots | 45,000 | HK$ 0 |
| 100 lots | 50,000 | HK$ 0 |
| 120 lots | 60,000 | HK$ 0 |
| 140 lots | 70,000 | HK$ 0 |
| 160 lots | 80,000 | HK$ 0 |
| 180 lots | 90,000 | HK$ 0 |
| 200 lots | 100,000 | HK$ 0 |
| 300 lots | 150,000 | HK$ 0 |
| 400 lots | 200,000 | HK$ 0 |
| 500 lots | 250,000 | HK$ 0 |
| 600 lots | 300,000 | HK$ 0 |
| 700 lots | 350,000 | HK$ 0 |
| 800 lots | 400,000 | HK$ 0 |
| 900 lots | 450,000 | HK$ 0 |
| 1,000 lots | 500,000 | HK$ 0 |
| 1,200 lots | 600,000 | HK$ 0 |
| 1,400 lots | 700,000 | HK$ 0 |
| 1,600 lots | 800,000 | HK$ 0 |
| 1,800 lots | 900,000 | HK$ 0 |
| 2,000 lots | 1,000,000 | HK$ 0 |
| 2,200 lots | 1,100,000 | HK$ 0 |
| 2,419 lots | 1,209,500 | HK$ 0 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Avg Daily HK Mkt Cap | --- |
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 12.38 |
|---|---|
| First Day Open | HK$ 11.92 |
| First Day Change | 7.65% |
| First Day Volume | 5106500.0 |
| First Day Turnover | 61579300.0 |
| Use of Proceeds | 1、約155.2百萬港元(相當于所得款項凈額的80%)將用于為核心產品HTD1801的持續臨床研發活動提供資金;
2、約9.7百萬港元(相當于所得款項凈額的5%)將用于為肥胖癥的HTD1804的持續研發提供資金;
3、約19.5百萬港元(相當于所得款項凈額的10%)將用于透過持續升級及加強FUSIONTXTM開發方式進行其他候選藥物的早期藥物發現及開發;
4、約9.7百萬港元(相當于所得款項凈額的5%)將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 沧州创融股权投资基金有限公司 | 109,106,250 HKD | — | 39.21% | — | 6 months | 2024-06-22 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉利平 | — |
| Company Secretary | 高麗萍;朱璧敏 | — |
Major Shareholders
| Major Shareholders & Holdings | 深圳市海普瑞藥業集團股份有限公司(23.61%);GREAT Mantra Group Limited(16.21%);百億投資有限公司(5.33%) |
|---|
Market Sentiment
The IPO of 君圣泰医药-B (02511) achieved a 32.22x oversubscription, indicating moderate retail demand but falling short of market frenzy levels. With a hit rate of 44.15%, over half of applicants walked away empty-handed, and the final offer price data is missing, limiting pricing commentary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Both A-tail and B-head applicants were allocated just 1 lot each, despite applying for 800 and 900 lots respectively—a mere 0.125% allocation, erasing the typical efficiency edge of B-head. This anomaly makes the B-head application cost-inefficient due to higher margin costs without any gain in shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
No demographic breakdown (Mainland/HK ratios, regional data) is available for this listing, possibly due to reporting gaps for pharmaceutical B-shares, limiting analysis of investor composition. Without this data, common trends like Guangdong dominance or mainland participation cannot be confirmed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




